Valo Therapeutics Secures €19M Capital for Cancer Research Expansion

Valo Therapeutics Oy, a Finnish biotechnology company, has secured a €19 million investment to further its innovative cancer immunotherapy research, conducted through the development of its PeptiCRAd platform. This investment round was European-centric, co-led by Indaco Venture Partners and CDP Venture Capital SGR, with significant contributions from ENEA Tech and Biomedical Foundation and Freeman Road, led by Dr. Paul Porter, representing Australian investors. The infusion of capital will facilitate the completion of Valo's Phase 1B study for its primary therapeutic candidate PeptiCRAd across Italy, Australia, and Germany, and will allow Valo to scale production for its oncolytic viruses in Southern Italy. The company's strategic expansion includes establishing a new operational entity, Valo Therapeutics Italy Srl, in Naples to advance cancer patient recruitment, treatment efforts, and support research activities in collaboration with local academic and scientific institutions. Key participants involved in this funding include Indaco Venture Partners, CDP Venture Capital SGR, and ENEA Tech and Biomedical. This initiative signifies a considerable advancement in biotechnology, promising to enhance treatment options for currently unmanageable solid tumors and encouraging further biotechnological innovations both in Italy and internationally.